DAWN Q1 2024 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$116,000

Operating Income

-$67M

Net Income

-$62M

EPS (Diluted)

$-0.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$327M

Total Liabilities

$30M

Stockholders' Equity

$297M

Cash & Equivalents

$270M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$116,000	-$89,000	-30.3%
Operating Income	-$67M	-$46M	-45.6%
Net Income	-$62M	-$42M	-47.2%